This review of allogeneic HCT in patients with chronic myelogenous leukemia (CML), myelofibrosis, and chronic myelomonocytic leukemia includes discussion of how the use of tyrosine kinase inhibitors (TKIs) affects clinicians’ decision-making on the timing to pursue transplantation in patients with these diseases. The authors note that while HCT is a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia, it is now typically used to treat CML patients in advanced stages with resistance or intolerance to TKIs.
Adekola K, et al. Bone Marrow Transplant